Gentian Diagnostics ASA (6FK) Stock Statistics & Valuation Metrics

Gentian Diagnostics ASA has a market cap or net worth of €71.23M. The enterprise value is €909.94M.

Gentian Diagnostics ASA has 15,422,350 shares outstanding. The number of shares has decreased by -2.65% in one year.

Gentian Diagnostics ASA’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is 17.01%.

The current PE Ratio of Gentian Diagnostics ASA is 20.0. Gentian Diagnostics ASA’s PEG ratio is ―.

In the last 12 months, Gentian Diagnostics ASA had revenue of 152.07M and earned 45.29M in profits. Earnings per share was 2.94.

In the last 12 months, operating cash flow was 19.89M and capital expenditures -7.79M, giving a free cash flow of 12.11M billion.

Gentian Diagnostics ASA pays an annual dividend of ―, resulting in a dividend yield of ―

Gentian Diagnostics ASA upcoming earnings date is Oct 23, 2025, TBA (Confirmed).

Gentian Diagnostics ASA as a current ratio of 5.38, with Debt / Equity ratio of 1.60%

In the past 12 months, Gentian Diagnostics ASA has paid -25.23M in taxes.

Gentian Diagnostics ASA EV to EBITDA ratio is 16.80, with an EV/FCF ratio of 211.35.

Gentian Diagnostics ASA has €80.25M in cash and marketable securities with €4.34M in debt, giving a net cash position of €77.09M billion.

Gross margin is 54.19%, with operating margin of 10.34%, and net profit margin of 29.78%.

The average price target for Gentian Diagnostics ASA is ―, which is 11.43% higher than the current price. The consensus rating is ―